Biogen Inc. (0R1B.L)
USD 117.99
(1.06%)
USD 117.99
(1.06%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.37 Billion USD | -3.25% |
| 2022 | 4.35 Billion USD | -26.54% |
| 2021 | 2.48 Billion USD | -23.94% |
| 2020 | 5.73 Billion USD | -36.06% |
| 2019 | 7.77 Billion USD | 9.6% |
| 2018 | 6.75 Billion USD | 5.12% |
| 2017 | 6.09 Billion USD | -0.23% |
| 2016 | 5.87 Billion USD | 18.47% |
| 2015 | 5.61 Billion USD | 26.9% |
| 2014 | 4.66 Billion USD | 54.97% |
| 2013 | 3.02 Billion USD | 38.76% |
| 2012 | 2.25 Billion USD | 1.94% |
| 2011 | 2.1 Billion USD | 2.02% |
| 2010 | 1.62 Billion USD | 9.79% |
| 2009 | 1.8 Billion USD | -3.57% |
| 2008 | 1.66 Billion USD | 36.36% |
| 2007 | 1.27 Billion USD | 50.65% |
| 2006 | 875.67 Million USD | 9.2% |
| 2005 | 668.05 Million USD | 51.67% |
| 2004 | 522.42 Million USD | 169.71% |
| 2003 | -804.13 Million USD | -302.31% |
| 2002 | 257.75 Million USD | 4.12% |
| 2001 | 367.81 Million USD | 76.47% |
| 2000 | 208.43 Million USD | -37.7% |
| 1999 | 347.35 Million USD | 70.99% |
| 1998 | 215.22 Million USD | 16.29% |
| 1997 | 168.26 Million USD | 199.97% |
| 1996 | 56.09 Million USD | 205.5% |
| 1995 | 18.36 Million USD | 198.6% |
| 1994 | 6.14 Million USD | -60.33% |
| 1993 | 15.5 Million USD | -36.21% |
| 1992 | 24.3 Million USD | 595.92% |
| 1991 | -4.9 Million USD | -88.46% |
| 1990 | -2.6 Million USD | 85.64% |
| 1989 | -18.1 Million USD | -105.68% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 693 Million USD | 13.37% |
| 2024 Q2 | 811.2 Million USD | 34.8% |
| 2024 Q3 | 451 Million USD | -24.51% |
| 2023 Q4 | 623.2 Million USD | 67.66% |
| 2023 Q3 | 371.7 Million USD | -47.54% |
| 2023 Q1 | 577.1 Million USD | 12.04% |
| 2023 FY | - USD | -3.25% |
| 2023 Q2 | 708.6 Million USD | 22.79% |
| 2022 Q2 | 1.04 Billion USD | 40.7% |
| 2022 FY | - USD | -26.54% |
| 2022 Q4 | 515.1 Million USD | -46.95% |
| 2022 Q3 | 971 Million USD | -6.69% |
| 2022 Q1 | 739.6 Million USD | 13.44% |
| 2021 Q2 | 1.1 Billion USD | 1.63% |
| 2021 FY | - USD | -23.94% |
| 2021 Q3 | 913.2 Million USD | -17.57% |
| 2021 Q4 | 652 Million USD | -28.6% |
| 2021 Q1 | 1.09 Billion USD | 378.06% |
| 2020 FY | - USD | -36.06% |
| 2020 Q3 | 1.11 Billion USD | -47.33% |
| 2020 Q1 | 2.03 Billion USD | 14.8% |
| 2020 Q2 | 2.1 Billion USD | 3.79% |
| 2020 Q4 | -392 Million USD | -135.28% |
| 2019 Q3 | 2.08 Billion USD | 5.26% |
| 2019 Q2 | 1.98 Billion USD | 11.27% |
| 2019 FY | - USD | 9.6% |
| 2019 Q1 | 1.78 Billion USD | -4.25% |
| 2019 Q4 | 1.77 Billion USD | -15.2% |
| 2018 FY | - USD | 5.12% |
| 2018 Q3 | 2.01 Billion USD | 35.24% |
| 2018 Q2 | 1.48 Billion USD | -9.84% |
| 2018 Q1 | 1.65 Billion USD | 2.5% |
| 2018 Q4 | 1.86 Billion USD | -7.51% |
| 2017 Q3 | 1.82 Billion USD | 10.08% |
| 2017 Q1 | 1.56 Billion USD | -18.27% |
| 2017 Q4 | 1.61 Billion USD | -11.63% |
| 2017 Q2 | 1.65 Billion USD | 5.74% |
| 2017 FY | - USD | -0.23% |
| 2016 Q4 | 1.91 Billion USD | 22.79% |
| 2016 Q1 | 1.54 Billion USD | 3.07% |
| 2016 Q2 | 1.65 Billion USD | 7.08% |
| 2016 Q3 | 1.56 Billion USD | -5.82% |
| 2016 FY | - USD | 18.47% |
| 2015 FY | - USD | 26.9% |
| 2015 Q4 | 1.5 Billion USD | -1.72% |
| 2015 Q3 | 1.52 Billion USD | 11.33% |
| 2015 Q2 | 1.37 Billion USD | 11.56% |
| 2015 Q1 | 1.22 Billion USD | -3.37% |
| 2014 Q1 | 859.95 Million USD | 13.59% |
| 2014 Q3 | 1.27 Billion USD | 10.45% |
| 2014 FY | - USD | 54.97% |
| 2014 Q4 | 1.27 Billion USD | -0.06% |
| 2014 Q2 | 1.15 Billion USD | 34.05% |
| 2013 Q3 | 826.12 Million USD | 6.14% |
| 2013 FY | - USD | 38.76% |
| 2013 Q1 | 600.74 Million USD | 26.86% |
| 2013 Q2 | 778.34 Million USD | 29.56% |
| 2013 Q4 | 757.06 Million USD | -8.36% |
| 2012 Q1 | 518.59 Million USD | 11.48% |
| 2012 Q3 | 326.05 Million USD | -47.2% |
| 2012 Q4 | 473.56 Million USD | 45.24% |
| 2012 Q2 | 617.49 Million USD | 19.07% |
| 2012 FY | - USD | 1.94% |
| 2011 FY | - USD | 2.02% |
| 2011 Q4 | 465.21 Million USD | -20.2% |
| 2011 Q3 | 582.96 Million USD | 14.84% |
| 2011 Q2 | 507.61 Million USD | -4.28% |
| 2011 Q1 | 530.31 Million USD | -31.4% |
| 2010 Q1 | 395.09 Million USD | -18.92% |
| 2010 FY | - USD | 9.79% |
| 2010 Q4 | 773.02 Million USD | 169.01% |
| 2010 Q3 | 287.36 Million USD | -41.36% |
| 2010 Q2 | 490.03 Million USD | 24.03% |
| 2009 Q4 | 487.27 Million USD | 1.31% |
| 2009 Q3 | 480.96 Million USD | 32.96% |
| 2009 FY | - USD | -3.57% |
| 2009 Q1 | 441.9 Million USD | -14.22% |
| 2009 Q2 | 361.74 Million USD | -18.14% |
| 2008 FY | - USD | 36.36% |
| 2008 Q1 | 422.24 Million USD | -0.37% |
| 2008 Q2 | 451.1 Million USD | 6.83% |
| 2008 Q3 | 492.27 Million USD | 9.13% |
| 2008 Q4 | 515.14 Million USD | 4.65% |
| 2007 FY | - USD | 50.65% |
| 2007 Q2 | 330.89 Million USD | 5.89% |
| 2007 Q3 | 268.88 Million USD | -18.74% |
| 2007 Q4 | 423.81 Million USD | 57.62% |
| 2007 Q1 | 312.48 Million USD | 2397.69% |
| 2006 Q3 | 313.26 Million USD | 13.55% |
| 2006 Q4 | -13.6 Million USD | -104.34% |
| 2006 Q2 | 275.88 Million USD | -13.64% |
| 2006 Q1 | 319.47 Million USD | 42.53% |
| 2006 FY | - USD | 9.2% |
| 2005 Q4 | 224.14 Million USD | 33.03% |
| 2005 FY | - USD | 51.67% |
| 2005 Q2 | 233.08 Million USD | 24.59% |
| 2005 Q1 | 187.09 Million USD | 4.79% |
| 2005 Q3 | 168.49 Million USD | -27.71% |
| 2004 Q3 | 206.71 Million USD | 72.76% |
| 2004 Q4 | 178.54 Million USD | -13.63% |
| 2004 FY | - USD | 169.71% |
| 2004 Q1 | 35.16 Million USD | 103.34% |
| 2004 Q2 | 119.65 Million USD | 240.22% |
| 2003 Q1 | 74.48 Million USD | -19.5% |
| 2003 Q3 | 81.89 Million USD | 12.39% |
| 2003 Q4 | -1.08 Billion USD | -1312.38% |
| 2003 Q2 | 54.25 Million USD | -32.33% |
| 2003 FY | - USD | -302.31% |
| 2002 Q3 | 79.9 Million USD | 66.98% |
| 2002 Q4 | 79.49 Million USD | 57.01% |
| 2002 Q2 | 83.11 Million USD | -43.97% |
| 2002 Q1 | 103.61 Million USD | -12.68% |
| 2002 FY | - USD | 4.12% |
| 2001 Q2 | 88.83 Million USD | 12.61% |
| 2001 Q3 | 135.77 Million USD | 0.73% |
| 2001 Q4 | 101.76 Million USD | 23.61% |
| 2001 FY | - USD | 76.47% |
| 2001 Q1 | 95.34 Million USD | -21.03% |
| 2000 Q1 | 92.26 Million USD | -104.77% |
| 2000 Q3 | 70.04 Million USD | -53.04% |
| 2000 Q2 | 95.18 Million USD | 1261.33% |
| 2000 Q4 | 109.67 Million USD | 171.14% |
| 2000 FY | - USD | -37.7% |
| 1999 Q1 | 62.3 Million USD | -42.83% |
| 1999 Q3 | 83.4 Million USD | -9.54% |
| 1999 Q4 | 149.35 Million USD | 69.77% |
| 1999 FY | - USD | 70.99% |
| 1999 Q2 | 82.92 Million USD | 47.99% |
| 1998 Q2 | 40.7 Million USD | 15.3% |
| 1998 Q4 | 107.52 Million USD | 125.62% |
| 1998 FY | - USD | 16.29% |
| 1998 Q1 | 35.3 Million USD | -65.21% |
| 1998 Q3 | 48.3 Million USD | 18.67% |
| 1997 Q3 | 27.4 Million USD | -1.08% |
| 1997 FY | - USD | 199.97% |
| 1997 Q1 | 23.4 Million USD | -54.29% |
| 1997 Q2 | 27.7 Million USD | 18.38% |
| 1997 Q4 | 101.46 Million USD | 270.31% |
| 1996 FY | - USD | 205.5% |
| 1996 Q4 | 51.19 Million USD | 40.64% |
| 1996 Q3 | 36.4 Million USD | 382.17% |
| 1996 Q2 | -12.9 Million USD | -44.94% |
| 1996 Q1 | -8.9 Million USD | -127.25% |
| 1995 Q3 | -4.2 Million USD | 16.0% |
| 1995 Q4 | 32.66 Million USD | 877.64% |
| 1995 FY | - USD | 198.6% |
| 1995 Q2 | -5 Million USD | -92.31% |
| 1995 Q1 | -2.6 Million USD | -110.86% |
| 1994 FY | - USD | -60.33% |
| 1994 Q1 | 7.7 Million USD | 149.68% |
| 1994 Q2 | -5.3 Million USD | -168.83% |
| 1994 Q3 | -24.1 Million USD | -354.72% |
| 1994 Q4 | 23.94 Million USD | 199.37% |
| 1993 FY | - USD | -36.21% |
| 1993 Q2 | 10.8 Million USD | 65.06% |
| 1993 Q1 | 8.3 Million USD | -65.27% |
| 1993 Q4 | -4.7 Million USD | -354.1% |
| 1993 Q3 | 6.1 Million USD | -55.47% |
| 1992 FY | - USD | 595.92% |
| 1992 Q3 | 7.5 Million USD | 266.67% |
| 1992 Q4 | 23.9 Million USD | 218.67% |
| 1992 Q2 | -4.5 Million USD | -40.63% |
| 1992 Q1 | -3.2 Million USD | -28.0% |
| 1991 FY | - USD | -88.46% |
| 1991 Q2 | -700 Thousand USD | -333.33% |
| 1991 Q4 | -2.5 Million USD | -31.58% |
| 1991 Q3 | -1.9 Million USD | -171.43% |
| 1991 Q1 | 300 Thousand USD | -76.92% |
| 1990 Q1 | -400 Thousand USD | 94.44% |
| 1990 Q4 | 1.3 Million USD | 192.86% |
| 1990 Q3 | -1.4 Million USD | 39.13% |
| 1990 Q2 | -2.3 Million USD | -475.0% |
| 1990 FY | - USD | 85.64% |
| 1989 Q2 | 6.9 Million USD | -14.81% |
| 1989 FY | - USD | 8.59% |
| 1989 Q1 | 8.1 Million USD | 130.11% |
| 1989 Q3 | -2.1 Million USD | -195.65% |
| 1989 Q4 | -2.2 Million USD | -9.09% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 77.991% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 788.058% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 993.619% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 2120.399% |
| uniQure N.V. | -253.1 Million USD | 1039.154% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 2681.479% |
| bluebird bio, Inc. | -167.16 Million USD | 1521.982% |
| Imunon, Inc. | -20.78 Million USD | 11537.631% |
| Dynavax Technologies Corporation | 9.66 Million USD | -24491.351% |
| Editas Medicine, Inc. | -163.11 Million USD | 1557.236% |
| Illumina, Inc. | -608 Million USD | 490.954% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 629.383% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 26.996% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | -104.201% |
| Myriad Genetics, Inc. | -67.8 Million USD | 3605.9% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -471.257% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 641.216% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -2319.043% |
| Verastem, Inc. | -83.16 Million USD | 2958.139% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 121.076% |
| Waters Corporation | 1.02 Billion USD | -132.526% |
| Nektar Therapeutics | -243.1 Million USD | 1077.759% |
| Perrigo Company plc | 646.2 Million USD | -267.843% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 5449.182% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 2390.157% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 6475.56% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -666.072% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 2818.84% |
| Evolus, Inc. | -41.81 Million USD | 5785.243% |
| Adicet Bio, Inc. | -136.53 Million USD | 1840.946% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 2801.597% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 48.928% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 1683.527% |
| FibroGen, Inc. | -261.4 Million USD | 1009.317% |
| Agilent Technologies, Inc. | 1.67 Billion USD | -41.741% |
| OPKO Health, Inc. | -65.51 Million USD | 3728.121% |
| Homology Medicines, Inc. | -47.75 Million USD | 5077.385% |
| Geron Corporation | -174.78 Million USD | 1459.98% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 1141.991% |
| Exelixis, Inc. | 196.6 Million USD | -1109.042% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 2457.503% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 4363.218% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 569.471% |
| Zoetis Inc. | 3.68 Billion USD | 35.495% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 1156.487% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 4800.229% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 48.384% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 6687.772% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 1133.433% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -2094.343% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -425.947% |
| Blueprint Medicines Corporation | -474.61 Million USD | 600.83% |
| Insmed Incorporated | -654.73 Million USD | 463.045% |
| TG Therapeutics, Inc. | 26.1 Million USD | -9007.28% |
| Incyte Corporation | 919.42 Million USD | -158.531% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 570.414% |